Cybin Inc. (OTCMKTS:CYBN - Get Free Report)'s stock price fell 4.3% on Wednesday . The company traded as low as $10.20 and last traded at $10.25. 204,600 shares were traded during mid-day trading, an increase of 10% from the average session volume of 186,805 shares. The stock had previously closed at $10.71.
Cybin Trading Down 4.3 %
The firm has a market cap of $204.92 million, a price-to-earnings ratio of -1.54 and a beta of 0.38. The firm has a 50-day moving average of $10.19 and a two-hundred day moving average of $3.74.
Cybin Company Profile
(
Get Free Report)
Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation.
Featured Articles
Before you consider Cybin, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cybin wasn't on the list.
While Cybin currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
